Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases

Jafarzadeh, Abdollah; Nemati, Maryam; Khorramdelazad, Hossein; Hassan, Zuhair Mohammad

doi:10.1016/j.intimp.2019.02.026

Cited by 43 publications

(38 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conclusions from Table 2: Cimetidine antagonizes histamine’s immuno-suppressive effects and has powerful stimulatory effects on blood cells such as neutrophils and monocytes, and also macrophages, dendritic cells, NK cells, T-helpers, and CD8 + cytotoxic T cells [214]. For a review of cimetidine’s immunological actions see Pantziarka et al [215].…”

Section: Discussionmentioning

confidence: 99%

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer

Koltai¹,

Cardone

Reshkin

2019

IJMS

View full text Add to dashboard Cite

Low dose metronomic chemotherapy (MC) is becoming a mainstream treatment for cancer in veterinary medicine. Its mechanism of action is anti-angiogenesis by lowering vascular endothelial growth factor (VEGF) and increasing trombospondin-1 (TSP1). It has also been adopted as a compassionate treatment in very advanced human cancer. However, one of the main limitations of this therapy is its short-term effectiveness: 6 to 12 months, after which resistance develops. pH-centered cancer treatment (pHT) has been proposed as a complementary therapy in cancer, but it has not been adopted or tested as a mainstream protocol, in spite of existing evidence of its advantages and benefits. Many of the factors directly or indirectly involved in MC and anti-angiogenic treatment resistance are appropriately antagonized by pHT. This led to the testing of an association between these two treatments. Preliminary evidence indicates that the association of MC and pHT has the ability to reduce anti-angiogenic treatment limitations and develop synergistic anti-cancer effects. This review will describe each of these treatments and will analyze the fundamentals of their synergy.

show abstract

Section: Discussionmentioning

confidence: 99%

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer

Koltai¹,

Cardone

Reshkin

2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Histamine suppresses Toll-like receptor (TLR)-induced cytokine responses from peripheral blood mononuclear cells and this is reversed by famotidine [72]. Also, a recent review discusses the immunomodulatory properties of cimetidine [73].…”

Section: Where Else Could Histamine Antagonists Act To Modify Covid-19?mentioning

confidence: 99%

Histamine receptors and COVID-19

Ennis

Tiligada

2020

Inflamm. Res.

View full text Add to dashboard Cite

Objective Reports that the over-the-counter histamine H 2 receptor antagonist famotidine could help treat the novel coronavirus disease (COVID-19) appeared from April 2020. We, therefore, examined reports on interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and histamine receptor antagonists. Methods A systematic literature search was performed by 19 September 2020, and updated on 28 October 2020, in PubMed, Scopus, Cochrane Library and Google Scholar using (COVID-19 OR coronavirus OR SARS-CoV-2) AND (histamine antagonist OR famotidine OR cimetidine). ClinicalTrials.gov was searched for COVID-19 and (famotidine or histamine). Results Famotidine may be a useful addition in COVID-19 treatment, but the results from prospective randomized trials are as yet awaited. Bioinformatics/drug repurposing studies indicated that, among several medicines, H 1 and H 2 receptor antagonists may interact with key viral enzymes. However, in vitro studies have to date failed to show a direct inhibition of famotidine on SARS-CoV-2 replication. Conclusions Clinical research into the potential benefits of H 2 receptor antagonists in managing COVID-19 inflammation began from a simple observation and now is being tested in multi-centre clinical trials. The positive effects of famotidine may be due to H 2 receptor-mediated immunomodulatory actions on mast cell histamine–cytokine cross-talk, rather than a direct action on SARS-CoV-2.

show abstract

“…A diverse possible radioprotective drug could be Cimetidine, a histamine type II receptors blocker, which has been demonstrated to have an antisuppressor action. Cimetidine has also been employed efficaciously to reestablish immune activities in subjects with malignancies, hypogammaglobulinemia, and acquired immune deficiency syndrome-related complexes [ 77 ]. Some in vitro and in vivo experiments evaluated the radioprotective activity of cimetidine on lympho-hematopoietic cells.…”

Section: Radioprotective Agentsmentioning

confidence: 99%

Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies

et al. 2020

View full text Add to dashboard Cite

Radiation therapy plays a critical role in the management of a wide range of hematologic malignancies. It is well known that the post-irradiation damages both in the bone marrow and in other organs are the main causes of post-irradiation morbidity and mortality. Tumor control without producing extensive damage to the surrounding normal cells, through the use of radioprotectors, is of special clinical relevance in radiotherapy. An increasing amount of data is helping to clarify the role of oxidative stress in toxicity and therapy response. Radioprotective agents are substances that moderate the oxidative effects of radiation on healthy normal tissues while preserving the sensitivity to radiation damage in tumor cells. As well as the substances capable of carrying out a protective action against the oxidative damage caused by radiotherapy, other substances have been identified as possible enhancers of the radiotherapy and cytotoxic activity via an oxidative effect. The purpose of this review was to examine the data in the literature on the possible use of old and new substances to increase the efficacy of radiation treatment in hematological diseases and to reduce the harmful effects of the treatment.

show abstract

Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases

Cited by 43 publications

References 90 publications

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer

Histamine receptors and COVID-19

Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies

Contact Info

Product

Resources

About